Evolve Private Wealth LLC Cuts Stock Position in Becton, Dickinson and Company $BDX

Evolve Private Wealth LLC decreased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 60.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,512 shares of the medical instruments supplier’s stock after selling 3,899 shares during the period. Evolve Private Wealth LLC’s holdings in Becton, Dickinson and Company were worth $381,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of BDX. Larson Financial Group LLC lifted its position in shares of Becton, Dickinson and Company by 1.7% during the fourth quarter. Larson Financial Group LLC now owns 3,230 shares of the medical instruments supplier’s stock worth $627,000 after purchasing an additional 53 shares in the last quarter. Atlantic Union Bankshares Corp grew its holdings in shares of Becton, Dickinson and Company by 0.9% in the fourth quarter. Atlantic Union Bankshares Corp now owns 6,108 shares of the medical instruments supplier’s stock valued at $1,185,000 after purchasing an additional 57 shares in the last quarter. Oakworth Capital Inc. increased its stake in Becton, Dickinson and Company by 4.3% during the 4th quarter. Oakworth Capital Inc. now owns 1,555 shares of the medical instruments supplier’s stock worth $302,000 after buying an additional 64 shares during the period. BOK Financial Private Wealth Inc. increased its stake in Becton, Dickinson and Company by 7.3% during the 2nd quarter. BOK Financial Private Wealth Inc. now owns 1,073 shares of the medical instruments supplier’s stock worth $162,000 after buying an additional 73 shares during the period. Finally, Keating Financial Advisory Services Inc. lifted its holdings in Becton, Dickinson and Company by 41.6% during the 2nd quarter. Keating Financial Advisory Services Inc. now owns 252 shares of the medical instruments supplier’s stock worth $38,000 after buying an additional 74 shares in the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Roland Goette sold 2,438 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the sale, the executive vice president owned 14,856 shares in the company, valued at $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at $20,380,155. This trade represents a 3.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 11,704 shares of company stock valued at $1,963,618. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $189.87 on Wednesday. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. The company has a fifty day simple moving average of $163.37 and a 200-day simple moving average of $160.60. The stock has a market cap of $52.32 billion, a P/E ratio of 57.19, a price-to-earnings-growth ratio of 13.44 and a beta of 0.19. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $193.07.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The firm had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same quarter in the prior year, the company posted $3.68 earnings per share. Becton, Dickinson and Company’s revenue for the quarter was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities analysts expect that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be issued a $1.05 dividend. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio is presently 126.51%.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Citigroup restated a “buy” rating on shares of Becton, Dickinson and Company in a research note on Thursday, August 13th. Piper Sandler lifted their target price on Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a “neutral” rating in a report on Friday, August 7th. Evercore set a $180.00 target price on Becton, Dickinson and Company in a research note on Monday, July 6th. Wells Fargo & Company upped their price target on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Finally, UBS Group initiated coverage on Becton, Dickinson and Company in a research report on Tuesday, July 28th. They issued a “buy” rating and a $190.00 price target on the stock. Eight analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $185.67.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.